| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.16 | 0.006 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.33 | 0.006 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.083 | 0.006 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.087 | 0.007 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.007 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.095 | 0.008 |